Dr. Rafael L. Schmulevich

Timothy C. Wong, MD, is a cardiologist and is certified in internal medicine and cardiovascular disease by the American Board of Internal Medicine. He is director of the UPMC Hypertrophic Cardiomyopathy Center (HCM Center), associate director of the UPMC Cardiovascular Magnetic Resonance Center, and an assistant professor of medicine at the University of Pittsburgh School of Medicine. He received his medical degree from New York University School of Medicine and completed his cardiovascular disease fellowship at the University of Pittsburgh Medical Center. Dr. Wong is highly rated in 13 conditions, according to our data. His top areas of expertise are Hypertrophic Cardiomyopathy (HCM), Cardiomyopathy, Subvalvular Aortic Stenosis, Familial Hypertrophic Cardiomyopathy, and Heart Transplant.

Catalin Toma, MD, is an interventional cardiologist and is certified in cardiovascular disease and interventional cardiology by the American Board of Internal Medicine. He currently serves as director of interventional cardiology for the Heart and Vascular Institute and director of the Interventional Fellowship at UPMC. He is an assistant professor of medicine at the University of Pittsburgh School of Medicine. He received his medical degree from Grigore T. Popa University of Medicine and Pharmacy in Iasi, Romania. Following a post-doctoral fellowship at Johns Hopkins in Baltimore, he completed an internal medicine residency at St. Luke’s Roosevelt Hospital Center in New York City and a fellowship in cardiovascular disease and interventional cardiology at UPMC. Dr. Toma joined the UPMC Heart and Vascular Institute in 2007. He currently leads the Chronic Total Occlusion Program as well as the Pulmonary Vascular Interventional Program at UPMC Presbyterian Hospital. He is an integral part of the Structural Heart Program with interests in the aortic and tricuspid space. Additional interests include intracoronary imaging and mechanical circulatory support. Dr. Toma has had an extensive amount of publications and presentations over his career, has several invention patents, and serves as a clinical study leader at local and national levels. View Dr. Toma's full list of publications from PubMed. Dr. Toma is highly rated in 18 conditions, according to our data. His top areas of expertise are Pulmonary Embolism, Acute Coronary Syndrome, Heart Attack, Percutaneous Coronary Intervention (PCI), and Aortic Valve Replacement.

Dr. Prem Soman, MD, PhD, is a cardiologist certified in cardiovascular disease and internal medicine by the American Board of Internal Medicine. He is an associate professor of medicine (cardiology) and clinical and translational science at the University of Pittsburgh School of Medicine. He is director of the Cardiac Amyloidosis Center and nuclear cardiology at the UPMC Heart and Vascular Institute. Dr. Soman had his initial medical training in India, followed by a Ph.D. from the UK, residency at the Lehigh Valley Hospital, Allentown, Pa., and fellowships in cardiology and advanced cardiac imaging at the Tufts Medical Center, Boston, Mass. Dr. Soman sees patients with a variety of cardiac conditions including coronary disease, hypertension, arrhythmias, heart failure, and pericardial disease. He is a specialist in cardiac amyloidosis and nuclear cardiology, fields in which he is well-known for his research and numerous peer-reviewed publications. He has held many leadership positions in national societies including the American College of Cardiology and was President of the American Society of Nuclear Cardiology in 2018. View Dr. Soman's full list of publications from PubMed. LGBTQIA+ Affirming: This provider has completed training on how to create a safe, comfortable, and welcoming environment for LGBTQIA+ patients. This provider may or may not offer LGBTQIA+ specific medical or surgical care. Please ask when scheduling. Dr. Soman is highly rated in 10 conditions, according to our data. His top areas of expertise are Cardiac Amyloidosis, Transthyretin Amyloidosis, Transthyretin Amyloid Cardiomyopathy, and Primary Amyloidosis.